Member Info for DJB67

Yep, fantastic news! CIPN trial now ready to roll into recruitment and dosing phase.

Delisting is not the same as the company being dissolved. It is simply a matter of taking to company private and off the Aquis stock exchange. All shareholders continue to hold the same number of shares after the delist. So if as you say they do get a drug to market and the company makes millions, all shareholders will benefit.

And yes, other than the Phase 1 Pharmacokinetic trial which is funded by the company (Charles provided £2m last year for this and operational costs), the other trials for Endometriosis and Chemotherapy Induced Neuropathic Pain are being paid for by NHS Scotland, not shareholders. See the RNS that were issued which detail the £1.5m funding provided.

And that’s not to say there is no risk. Clearly this is a high risk investment. It’s a tiny company hoping to make big inroads into the treatment of pain. And you have said on many occasions not many companies will actually make the breakthrough. Hopefully this one will.

Of course I am. Actually called Charley! 🤣

Haha! Bye then….

So if you can’t prove anything until it happens you cannot say you know anything 100%. You are making assertions as if you have facts and actual knowledge, which you do not.

And as I’ve said before, there is very little external shareholder money that has been put into the business (approx £400k in 8 years).

And the £10m Charles has put in has gone into 8 years of day to day operational costs, as well as capital expenditure of £2m needed to build the trial growing facilities in Lincolnshire, 3 years of staff costs in the growing facility during trials, 100% acquisition of Tiamat Agriculture, 100% acquisition of DJT Plants, 100% acquisition of MRX Global and it’s subsidiary MRX Medical and more recently £1m into the Phase 1 trial just completed in Australia.

You say I speak ******, which I assume is an expletive, but at least I can state facts, discuss the business with knowledge and explain my rationale for my opinion. You have never been able to do any of that.

You state this is not a Ponzi scheme, but you still don’t answer how the board of directors are fleecing the shareholders, as you have previously stated. As I’ve now asked you 3 times to provide an explanation and each time failed to answer, I’ll assume you can’t answer and therefore will conclude that you are simply making accusations with absolutely no foundation.

You have finally accepted that Charles has funded the business to over £10m, and therefore you must accept that he funds attendance at conferences and associated travel.

You say Charles won’t lose his £10m regardless of what happens. Please explain how that will be since there are no physical assets owned by the business. Tell me how Charles will recover his £10m if the business does not succeed.

And you state that you know 100% that the business is not as rosey as we paint. If you are 100% certain, I assume you therefore have evidence to support your claim. So please explain what you mean by this and detail the evidence you have for making this statement.

How can you dispute facts.

It is absolute fact that Charles has invested over £10m. It is fact that a few HNW investors plus a few small shareholders have put in approx £400k. And therefore it is fact that Charles funds travel and conferences. He has also stated in the RNS on Wednesday that he will continue to fund the business for the foreseeable future. If you dispute these facts then you know absolutely nothing of this company and how it has been funded.

And yes, shareholders are here to make money, in the long term. It’s clear a few want out as they don’t want to hold an unlisted share, which is understandable, but the vast majority are still holding. There are approx 1bn shares held by private shareholders, and so far this week we’ve seen less than 43m shares sold (approx 1% of shares in issue) and most have been bought by other shareholders.

And you question the first 3 lines of answer to question 3!? So you actually think this company is listed on AIM?

You really do need to do your research.

And you still haven’t answered my question! You bluff and bluster but never answer the question. Go on I dare you, show how much you know about the business.

Or continue with the same old drivel that nobody listens to.

So for the last time I’ll repeat my question and try to have a go at answering it.

Why and how are the board of directors fleecing shareholders?

I note you haven’t answered my question. Is that because you don’t have an explanation? I’ll answer yours anyway.

Q1. Who funds attendance and travel at conferences? The company does. Who has provided 96% of the funding to the company over the last 8 years? Charles Morgan, the Exec Chairman. Therefore ultimately Charles funds their attendance and travel for conferences.

Q2. I’ll answer this but in my mind it’s irrelevant. They’d have about £10k.

And the reason it is irrelevant is that the majority of investors in Ananda are here for the long term, and for when a buy-out comes along, so the value of a shareholders holding at this point is just a meaningless number.

Anyone who bought shares to trade was always on hiding to nothing, because of the lack of liquidity. And there are 2 reasons for the lack of liquidity. First, over 78% of shares are held by the board of directors, mostly Charles and they aren’t going to be selling. And second, the remainder of shareholders are holding for the long term buy-out. It’s evidenced in the small volume of shares traded per day this week, when we’ve seen more traded than I can ever remember. Take Monday, approx 30m shares bought and sold. 30m equates to 0.6% of total shares in issue. It’s been even less each day Tuesday to Thursday. It’s nothing, and just shows the lack of interest in selling even after the news to delist.

Q3. Why did they come to AIM? First of all, they didn’t come to AIM, they’ve never been on AIM. They are on Aquis. And they came to Aquis to raise external capital. That clearly hasn’t happened hence why Charles has provided the vast majority of funding. The company believes the reason external funding has not been available is because it sits at a crossroads of 4 out of favour sectors, namely Cannabis, Micro Cap, Pre-Revenue and Early Stqge Bio-tech.

And thanks, but I’ve watched every presentation since I first invested almost 5 years ago.

So now, I’ve answered your questions, how about you answer mine. And I’ll repeat it here…. Why and how are the board of directors fleecing shareholders?

Supersport - See my comments in the other thread for more detail, but for all fund raises the chairman has almost exclusively funded the company so exactly how are they fleecing shareholders?

Supersport - I’m interested to hear your explanation of why you think there are ‘snouts in the trough’.

I assume you are referring to the board. But can you tell me how that sits with the fact that the Exec Chairman, Charles Morgan, has so far invested over £10m in the business in the last 8 years. In fact, other than a couple of HNW investors and a few small shareholders who have put in approx £400k over the last 3 years, no one else has actually funded the company. Further he and the CEO Melissa Sturgess haven’t taken their directors fees for the last 2 years.

Others have accused Ananda of being a lifestyle company and I explained the above to them and asked for an explanation for their accusations. I received no response.

So if the directors really are taking money from the business as you imply, the only money they are taking is their own.

Perhaps you can explain your thinking. Thanks.

The RNS today was in response to questions raised in the Ananda Pharma Telegram group. I’d say they are a good set of responses that clarify the boards position and which indicate to me that nothing is changing in terms of the company strategy.

From a shareholder perspective, the biggest impact is the loss of the ISA tax break, assuming of course that money is going to be made. Secondary is the fact that shareholders will no longer be able to sell shares when they want, and will have to wait for a buy-out to realise anything from their investment. That said, trading was never an option given the lack of liquidity and personally I was always here for the long term and intending to stay invested for a buy-out so I’m not too concerned about this.

One key point to note in the responses is that if the delist is approved and the company goes private, Charles intends to continue to fund the company for the foreseeable future on top of his £10m already invested. The response also states that Charles would not continue to fund should the shareholders vote against the delist resolution. To me, and in the absence of any other funding, that says the company will be forced to dissolve.

So, if you vote in favour of the delist you are voting for the company to continue. If you vote against, you are voting for the end.

Shareholders may not like the company going private but to me there is little option but to vote in favour of the delist. Everyone has to make their own choice.

Phase 1 Pharmacokinetic trial in Australia funded by the company has just completed. Yes, only small scale, but necessary. Results due Q1 2026.

Endo and CIPN trials ongoing with patient recruitment and dosing expected to start early 2026. Remember, these 2 trials are not funded by the company. Just over £1.5m has been provided by NHS Scotland for Edinburgh University to undertake the trials using the Ananda MRX1 formulation.

Ananda is no longer part of the Epilepsy Phase 3 trials. If you want the full explanation, it is contained in a series of emails I exchanged with Charles. These are documented in the Ananda Telegram group.

Oh look who is back spouting the usual garbage it’s Mr Cookoo, otherwise known as Garry!

I have to say I’m at a loss at why you keep calling this a lifestyle company. A lifestyle company is one that raises cash from investors where the board use the cash to fund their own lifestyle.

Yet this company has been funded since it was created almost entirely from the personal wealth of the chairman Charles Morgan. To date over £9m! Yes, I’ll say that again Nine Million Pounds!!

Yes, there have been a few HNW individuals invest relatively small amounts (£300-400k estimate), plus for the last 2 fund raises existing investors have been invited to join the fund raise albeit again for relatively small sums (less than £100k for each raise)

So, instead of constantly repeating your completely baseless and unfounded accusations how about you explain to us all why you think this is a lifestyle company. And whilst you are at it, if you have reported the company to the FCA, let’s see the detail of the case you have raised. Provide some details on it. The case number, who is handling the case, the evidence you have submitted, etc etc.

Until you make your case and provide the evidence of a FCA investigation you’ll continue to be regardless as someone who is simply here to disrupt the board.

It’s an interesting proposition if you are prepared to take a long term view.

A few of us are in a Telegram group if you are interested in joining a more active conversation about the company. Search for ananda_pharma.

Where do get 10 from?

PK study is 20 healthy people

CIPN is approx 100

Endometriosis is approx 100

Epilepsy in children is 240

Epilepsy in adults is 240

And they talk about GW Pharma because it is the aspiration to replicate their success. They have clearly set themselves a target to achieve, which is no bad thing in my view.

I’d prefer that they focus on the 5 trials that are already underway rather than spreading themselves too thin, although it would be nice to see them progress the HFpEF opportunity in time.

I’m also not too concerned about whether about whether PI’s engage or are interested. Most only come with small change and want to trade, which doesn’t actually help the company. What I’d like to see is engagement of a few more serious long term investors, maybe HNW individuals or even a partnership with a mid-tier pharma.

I don’t think they have been named. Probably worth a question to them on their website on The Hub though.

Oh look who is back! Normal for Norfolk! And once again, adding absolutely nothing of value to this board.

One day you might post something that is actually useful that we can debate, rather than your ridiculous and unfounded accusations.

Share price impacted over the last few weeks by significant selling, presumed to be from a distressed seller.

And yes, 4.25bn share in issue is significant. Approx half of these are held by the Chairman Charles Morgan which he has received in return for the approx £9m he has loaned the company over the last 5 years.

Key activities this year include:

Phase 1 Pharmacokinetic Trial in Australia has recently received approval to commence. Patient recruitment to start imminently.

Phase 2 trial for Endometriosis treatment has started and patient recruitment is stated to be starting in Autumn 2025.

Phase 2 trial for CIPN treatment has started and patient recruitment expected Q3 this year.

Phase 3 trials for both Childhood and Adult Epilepsy have just started. No timescale published yet for patient recruitment but expectation is sometime in 2026.

If you want to discuss Ananda with a group of investors, then you can join our Telegram group. Search for ananda_pharma